Dong‐Wan Kim - Concepedia

Author

Dong‐Wan Kim

Seoul National University Hospital ORCID

Also Known As

D.-W. Kim, David W. Kim, Dong-Wan Kim, DongWan Kim, Dongwan Kim, Dong‐Wan Kim, Dong‑Wan Kim, Ewa Wasilewska-Teśluk, Kim, Dong-Wan, Kim, Dongwan

727

Publications

32.6K

Citations

H-Index

170

Concepts

All Affiliations

Seoul National University Hospital Seoul National University Samsung Medical Center Sungkyunkwan University Asan Medical Center

About

Dong‐Wan Kim is an author at Seoul National University Hospital specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	47	130	16.1K
2	Health Sciences	25	48	8.2K
3	Engineering	13	13	1.2K
4	Natural Sciences	3	3	189
5	Management	1	1	47

Dong‐Wan Kim

261

Publications

31.4K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial Roy S. Herbst, Paul Baas, Dong‐Wan Kim, The Lancet Pembrolizumab Versus DocetaxelOncologyClinical TrialsImmune Checkpoint InhibitorPharmacotherapy	2015	6.4K
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer Solange Peters, D. Ross Camidge, Alice T. Shaw, New England Journal of Medicine	2017	2.4K
Virus-Enabled Synthesis and Assembly of Nanowires for Lithium Ion Battery Electrodes Ki Tae Nam, Dong‐Wan Kim, Pil J. Yoo, Science	2006	1.8K
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study D. Ross Camidge, Yung‐Jue Bang, Eunice L. Kwak, The Lancet Oncology OncologyMedicineUpdated ResultsPathologyBronchial Neoplasm	2012	1.3K
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer Alice T. Shaw, Todd M. Bauer, Filippo de Marinis, New England Journal of Medicine	2020	1K
Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib Sae‐Won Han, Tae‐You Kim, Pil Gyu Hwang, Journal of Clinical Oncology	2005	775
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity Peter Ballard, James Yates, Zhenfan Yang, Clinical Cancer Research	2016	704
Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study Keunchil Park, Eric B. Haura, Natasha B. Leighl, Journal of Clinical Oncology	2021	597
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial Dong‐Wan Kim, Marcello Tiseo, Myung‐Ju Ahn, Journal of Clinical Oncology Lymphoid NeoplasiaAlk-positive NsclcMedicinePharmacologyObjective Response Rate	2017	577
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim, The Lancet Oncology MedicineImmunologyPathologyImmune Checkpoint InhibitorCancer Treatment	2018	568

Page 1